 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Prabhudas Lilladher is bullish on Indoco Remedies has recommended buy rating on the stock with a target price of Rs 385 in its research report dated October 19, 2023.

Buy Indoco Remedies; target of Rs 385: Prabhudas Lilladher

Indoco Remedies Standalone September 2023 Net Sales at Rs 473.39 crore, up 9.41% Y-o-Y

The share touched a 52-week high of Rs 423.10 on January 2, 2023 and a 52-week low of Rs 307.00 on April 26, 2023.

Indoco Remedies down 3% after 4 observations from FDA for Goa facility

Indoco Remedies has fixed 19 September 2023 as record date for final dividend for FY 2023. The dividend, if approved, shall be paid on or after 29 September 2023. 

Indoco Remedies fixes record date for final dividend 

Indoco Remedies announced that the 76th Annual General Meeting (AGM) of the company will be held on 26 September 2023.

Indoco Remedies to convene AGM

Prabhudas Lilladher is bullish on Indoco Remedies has recommended buy rating on the stock with a target price of Rs 380 in its research report dated July 25, 2023.

Buy Indoco Remedies; target of Rs 380: Prabhudas Lilladher

Indoco Remedies Standalone June 2023 Net Sales at Rs 422.88 crore, up 3.67% Y-o-Y

Indoco Remedies will hold a meeting of the Board of Directors of the Company on 25 July 2023.

Indoco Remedies to announce Quarterly Result

Net Sales are expected to increase by 6.8 percent Y-o-Y (up 1.8 percent Q-o-Q) to Rs 435.9 crore, according to Nirmal Bang.

Indoco Remedies Q1 PAT may dip 0.1% YoY to Rs 38.5 cr: Nirmal Bang

The European agency conducted an inspection at Indocos manufacturing facility for solid oral dosage form in Goa (Plant-III) from 20 April 2023 to 25 April 2023.The EU GMP certification issued by the German Health Authority (LAGeSo) confirms that the site complies with the GMP requirements as referred to in the EC Directive. The EU certification will support supplies of drug products registered in Europe and other regions from this manufacturing site.Aditi Panandikar, managing director of Indoco Remedies said, “The EU GMP certification for our site in Goa (Plant III) complements our unswerving efforts to supply quality and affordable medicines in Europe and other geographies. We remain fully committed to adhering to cGMP standards and ensuring the delivery of quality products to our valued customers and patients worldwide.”Indoco Remedies is engaged in the manufacturing and marketing of Formulations (finished dosage forms) and active pharmaceutical ingredients (APIs).The pharmaceutical companys standalone net profit tumbled 37.16% to Rs 25.37 crore in Q4 FY23 from Rs 40.37 crore recorded in Q4 FY22. Revenue from operations grew by 6.94% year on year to Rs 428.05 crore in the quarter ended 31 March 2023.The scrip declined 0.09% to end at Rs 321.15 on the BSE.

Indoco Remedies' Goa facility gets EU GMP certificate

Indoco Remedies Ltd. engages in manufacturing and marketing of Formulations (Finished Dosage Forms) and active pharmaceutical ingredients. It operates through the Pharmaceutical Products segment. The company was founded by Govind Ramnath Kare in 1945 and is headquartered in Mumbai, India.

Market Cap	36.51B
Volume (M)	320,463.00
52-Wk High	423.90
52-Wk Low	306.40

INDOCO.NSE Indoco Remedies Ltd

About

Feed

News

Sentiment

Fundamentals